Join us in Booth #203 at the NCBC Annual Interdisciplinary Breast Center Conference
From the world leader in artificial intelligence for breast imaging, discover the ProFound impact iCAD’s award-winning portfolio of cancer detection, density assessment, and risk evaluation solutions can have on your reading workflow.
“We have had ProFound AI for about two years now, and the way we utilize it has grown as we’ve learned to trust the technology more. Other AI technologies simply do not deliver the level of performance, speed, and accuracy that ProFound AI offers.”
– Meghan Musser, DO, Medical Director for Breast Imaging at Kettering Health
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Join us for a revolutionizing event as NCoBC leadership and advocacy organizations join forces in a new way for improving the standards of breast care and breast cancer survivorship.
Mark Traill, MD, University of Michigan Health-West will discuss his experience with accessing the revolution in detection and risk assessment in a presentation titled, “Why AI?” from 2:45-3:30 pm.
"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat." - Lorem ipsum
"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat." - Lorem ipsum
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Unrivaled by any other AI solution available today, ProFound AI improves radiologists’ sensitivity by 8 percent, and reduces false positives and unnecessary patient recall rates by 7.2 percent.
The latest version offers up to a 10% incremental improvement in specificity performance while maintaining an industry-leading high sensitivity level.
ProFound AI delivers unmatched, clinically proven time-savings benefits to radiologists, slashing reading time by 52.7%.
Further, Certainty of Finding and Case Scores assist in prioritizing caseload and clinical decision-making, reducing physician burnout.
With thousands of installations worldwide, ProFound AI offers multi-vendor compatibility and seamlessly integrates into the diagnostic process.
Now compatible with Hologic Clarity HD™!
Today’s unprecedented screening challenges call for unparalleled AI solutions, streamlining workflow and elevating outcomes.
ProFound AI flexibly integrates with major PACS, offering an intuitive, system-wide solution for improved workflow and decision support in any reading environment.
With market-leading agility, ProFound AI offers a practical enterprise-wide solution with powerful results.
With access to our complete portfolio of cancer detection, density assessment and risk evaluation solutions on one centralized server, streamlined deployment of state-of-the-art breast imaging technology at scale is simple.
Now available for 2D and 3D mammography, ProFound AI® Risk is the world’s first clinical decision support tool that provides an accurate short-term, breast cancer risk estimation that is truly personalized for each woman.
Specifically designed to factor in racial and ethnic backgrounds, ProFound AI Risk offers an inclusive, first-in-kind approach to precision screening.
"Et harum quidem rerum facilis est et expedita distinctio!"
"Nam libero tempore, cum soluta nobis est eligendi."
"Temporibus autem quibusdam et aut officiis debitis!"
1. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm. Accessed 1-19-22. FDA 510K submissions K182373, K201019, K193229.
2. Conant, E et al. (2019). Improving Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis. Radiology: Artificial Intelligence. 1 (4). Accessed via https://pubs.rsna.org/doi/10.1148/ryai.2019180096
3. Based on publicly available data as of September 2021. For GE and Hologic only. Uses 2D synthesized images.
4. iCAD data on file.